TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive Breast Cancer
Interventions: DRUG: TAK-228|DRUG: Tamoxifen
Sponsor: The Methodist Hospital Research Institute
Collaborators: Millennium Pharmaceuticals, Inc.